Results 61 to 70 of about 8,420 (208)

Bioanalytical RP-HPLC method development and validation for estimation of azelnidipine and Olmesartan medoxomil in human plasma

open access: yesJournal of medical pharmaceutical and allied sciences, 2022
An accurate, rapid and simple reversed-phase high performance liquid chromatography (RP-HPLC) bioanalytical method was developed for estimation of Azelnidipine (AZP) and Olmesartan medoxomil (OLM)in human plasma.
A. Bhosale
semanticscholar   +1 more source

Linking FHIR‐Based Medication Data to a Computable Algorithm for Heart Medication Optimization: A Critical Component of Any Medication Learning Health System

open access: yesLearning Health Systems, Volume 10, Issue 1, January 2026.
ABSTRACT Introduction Despite strong evidence supporting guideline‐directed medical therapy (GDMT) for heart failure with reduced ejection fraction (HFrEF), a significant gap persists in the consistent application of these therapies. This shortfall has prompted organizations like the American College of Cardiology to recommend leveraging electronic ...
Joey LeGrand   +5 more
wiley   +1 more source

Development and Validation of a Chromatography Method Using Tandem UV/Charged Aerosol Detector for Simultaneous Determination of Amlodipine Besylate and Olmesartan Medoxomil: Application to Drug-Excipient Compatibility Study

open access: yesJournal of Analytical Methods in Chemistry, 2017
A study was carried out to investigate compatibility of amlodipine besylate and olmesartan medoxomil with a variety of pharmaceutical excipients. Both drugs are antihypertensive agents that can be administered alone, in monotherapy, or in pharmaceutical ...
Ariadne M. Brondi   +2 more
doaj   +1 more source

Synthesis and Physicochemical Characterization of the Process-Related Impurities of Olmesartan Medoxomil. Do 5-(Biphenyl-2-yl)-1-triphenylmethyltetrazole Intermediates in Sartan Syntheses Exist?

open access: yesMolecules, 2015
During the process development for multigram-scale synthesis of olmesartan medoxomil (OM), two principal regioisomeric process-related impurities were observed along with the final active pharmaceutical ingredient (API). The impurities were identified as
Iwona Dams   +7 more
doaj   +1 more source

Bioequivalence Studies in Healthy Volunteers: Olmesartan Medoxomil

open access: yes, 2011
This study aimed to investigate the bioequivalence of test and reference formulations of 40mg olmesartan medoxomil (CAS 144689-63-4) in 36 healthy male volunteers.
Diler, Z. Irem   +3 more
core   +1 more source

Exposure the Hazardous Potential of Quinalphos: An In‐Depth Analysis for Environmental and Biological Effects on Human Health

open access: yesIET Systems Biology, Volume 20, Issue 1, January/December 2026.
This study elucidates pesticide docking onto proteins encoded by differentially expressed genes, revealing interaction networks involving chemicals, genes, proteins, drugs and diseases. It highlights structural insights, regulatory pathways and potential therapeutic or environmental implications, providing a comprehensive understanding of the ...
Jyoti Kant Choudhari   +4 more
wiley   +1 more source

Combination Therapy with Olmesartan and Amlodipine in the Treatment of Hypertension

open access: yesPharmaceuticals, 2009
Background: Combination therapy with antihypertensive agents utilises different mechanisms of action and may be responsible for a more effective decrease in blood pressure.
Menco G. Niemeijer, Ton J. Cleophas
doaj   +1 more source

Formulation and in-vitro evaluation of electrospun microfibers for enhanced solubility of Olmesartan medoxomil

open access: yesJournal of Applied Pharmaceutical Sciences
Olmesartan medoxomil (OLM), which is a biopharmaceutical classification system class II drug has low aqueous solubility, resulting in its poor bioavailability and therapeutic efficacy.
Sreenivas Patro Sisinthy   +3 more
semanticscholar   +1 more source

Safety and Drug–Drug Interaction Burden of Direct‐Acting Antiviral Therapy for Hepatitis C: A Single‐Center Community Hospital Analysis

open access: yesInternational Journal of Hepatology, Volume 2026, Issue 1, 2026.
Background Polypharmacy leads to drug–drug interactions (DDIs) with direct‐acting antivirals (DAAs). We quantified the DDI burden (Liverpool categories) and evaluated its association with effectiveness and safety. We assessed renal function as a predictor of adverse events (AEs) and reported loss to follow‐up (LTFU). Methods We retrospectively analyzed
Satoru Okabe   +6 more
wiley   +1 more source

Tablet Formulation Studies on Recrystallized Active Pharmaceutical Ingredients of Valsartan and Olmesartan Medoxomil [PDF]

open access: yes, 2021
Both the Valsartan (VAL) and Olmesartan medoxomil (OLM) are widely prescribed anti-hypertensive agents with angiotensin II type I receptor antagonistic activity.
Rao, TP.   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy